Cellular Signaling in Drug-induced Toxicity
Cellular Signaling in Drug-induced Toxicity
批准号:
9206162
负责人:
Namandje N Bumpus
金额:
$30.78万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-04-01 至 2019-01-31
关键词:
Acute Liver FailureAdverse eventAnabolismAnti-Retroviral AgentsAntioxidantsAntiviral AgentsApoptosisApoptoticAttenuatedBIM Bcl-2-binding proteinBax proteinBiochemicalBiological AssayBiological ModelsCell DeathCessation of lifeClinical MarkersCoupledCysteineDataEnzymesEventExhibitsGene Expression ProfilingGenesGeneticGenetic TranscriptionGlutathioneGoalsHepatocyteHepatotoxicityHistologyHumanImmunoblottingIn VitroInfectionKnockout MiceMacacaMass Spectrum AnalysisMeasuresMediatingMetabolismModelingMolecularMusNevirapineOxidative StressParentsPathway interactionsPatientsPharmaceutical PreparationsPreventionPrevention strategyProteinsPurine NucleotidesRNA InterferenceReporter GenesReportingResistanceRitonavirRodentRoleSamplingSignal PathwaySignal TransductionSmall Interfering RNATechniquesTestingTherapeuticToxic effectUp-RegulationViralVirus DiseasesWorkantiretroviral therapybasecytotoxicityefavirenzexperimental studyglucose metabolismin vitro Modelin vivoinhibitor/antagonistliquid chromatography mass spectrometryliver injurymRNA Expressionmetabolomicsnew therapeutic targetnovelnovel strategiespreventprotein expressionpublic health relevance
中文摘要
描述(由申请方提供):依法韦仑(EFV)和奈韦拉平(NVP)是目前处方的肝毒性同类抗逆转录病毒药物。最近,在体外使用原代人肝细胞报道了细胞信号传导途径在调节EFV代谢下游毒性中的主要作用。氧化应激的增加和促凋亡蛋白BimEL(Bcl-2相互作用的细胞死亡介质超长)的上调已被证明是至关重要的刺激EFV诱导的细胞死亡,NVP似乎通过相同的机制调节肝细胞死亡。该提案的目标是确定EFV和NVP上调BimEL的方式,同时也获得对介导肝细胞死亡的BimEL下游事件的机制理解。其目标如下:(1)测试促凋亡BimEL的遗传缺陷是否导致体内针对EFV和NVP介导的细胞死亡的保护:BimEL缺失小鼠将用于确定BimEL的缺失是否使小鼠对这些化合物刺激的肝毒性具有抗性;肝细胞中的RNA干扰研究将用于确定效应蛋白Bax和巴克的作用,在调节EFV和NVP诱导的肝细胞死亡中位于BimEL的下游; siRNA和报告基因测定将用于确定EFV和NVP调节BimEL转录的机制;(2)确定在原代人肝细胞中被抗逆转录病毒激活的促凋亡途径是否也在接受抗逆转录病毒治疗的猕猴中被激活;(3)探索谷胱甘肽途径在EFV和NVP诱导的肝毒性中的改变作用;将使用基于质谱的方法检查这些化合物对谷胱甘肽途径的影响,该方法将精确定量该途径的中间体/产物; RNA干扰将用于确定酶在谷胱甘肽途径中在EFV和NVP诱导的肝毒性中的作用。预计完成拟定研究将导致确定用于预防和治疗EFV和NVP介导的肝毒性的新型治疗靶点。
英文摘要
DESCRIPTION (provided by applicant): Efavirenz (EFV) and nevirapine (NVP) are currently prescribed antiretroviral drugs of the same class that are hepatotoxic. Recently, a major role for cellular signaling pathways in modulating toxicity downstream of EFV metabolism has been reported in vitro using primary human hepatocytes. Increased oxidative stress and the upregulation of the proapoptotic protein BimEL (Bcl-2 interacting mediator of cell death extra long) have been demonstrated to be crucial in the stimulation of EFV-induced cell death, and NVP appears to modulate hepatocyte death via the same mechanism. The goal of this proposal is to determine the manner in which EFV and NVP upregulate BimEL, while also gaining a mechanistic understanding of the events downstream of BimEL that mediate the hepatocyte death. The aims are as follows: (1) Test whether genetic deficiency of proapoptotic BimEL results in protection against EFV- and NVP-mediated cell death in vivo: BimEL null mice will be used to determine whether the absence of BimEL renders mice resistant to hepatotoxicity stimulated by these compounds; RNA interference studies in hepatocytes will be used to determine the role of effector proteins, Bax and Bak, that are downstream of BimEL in modulating EFV- and NVP-induced hepatocyte death; siRNA and reporter gene assays will be used to define the mechanism by which EFV and NVP regulate the transcription of BimEL; (2) determine if proapoptotic pathways that are activated by antiretrovirals in primary human hepatocytes are also activated in macaques receiving antiretroviral therapy; (3) probe a role for alteration of the glutathione pathway in EFV- and NVP-induced hepatotoxicity; the effects of these compounds on the glutathione pathway will be examined using a mass spectrometry-based approach that will precisely quantitate the intermediates/products of this pathway; RNA interference will be used to define the role of enzymes in the glutathione pathway in EFV- and NVP-induced hepatotoxicity. It is expected that completion of the proposed studies will lead to the identification of novel therapeutic targets for the potential prevention and treatment of EFV- and NVP-mediated hepatotoxicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Drug Phosphorylation and Aging
-
批准号:10217514
-
项目类别:
-
资助金额:$12.5万
-
财政年份:2020
-
负责人:Namandje N Bumpus
-
依托单位:
Developmental Pharmacology of Antiretroviral Metabolism in Mucosal Tissues
-
批准号:9244420
-
项目类别:
-
资助金额:$51.72万
-
财政年份:2017
-
负责人:Namandje N Bumpus
-
依托单位:
Tissue pharmacology imaging and modeling
-
批准号:8768697
-
项目类别:
-
资助金额:$53.94万
-
财政年份:2014
-
负责人:Namandje N Bumpus
-
依托单位:
Cellular Signaling in Drug-induced Toxicity
-
批准号:8912623
-
项目类别:
-
资助金额:$4.96万
-
财政年份:2013
-
负责人:Namandje N Bumpus
-
依托单位:
Cellular Signaling in Drug Induced Toxicity
-
批准号:9916512
-
项目类别:
-
资助金额:$36.03万
-
财政年份:2013
-
负责人:Namandje N Bumpus
-
依托单位:
Cellular Signaling in Drug-induced Toxicity
-
批准号:8636492
-
项目类别:
-
资助金额:$30.78万
-
财政年份:2013
-
负责人:Namandje N Bumpus
-
依托单位:
Cellular Signaling in Drug-induced Toxicity
-
批准号:9412474
-
项目类别:
-
资助金额:$30.78万
-
财政年份:2013
-
负责人:Namandje N Bumpus
-
依托单位:
Cellular Signaling in Drug Induced Toxicity
-
批准号:10016325
-
项目类别:
-
资助金额:$36.03万
-
财政年份:2013
-
负责人:Namandje N Bumpus
-
依托单位:
Cellular Signaling in Drug-induced Toxicity
-
批准号:8417385
-
项目类别:
-
资助金额:$30.78万
-
财政年份:2013
-
负责人:Namandje N Bumpus
-
依托单位:
Cellular Signaling in Drug Induced Toxicity
-
批准号:10227081
-
项目类别:
-
资助金额:$36.03万
-
财政年份:2013
-
负责人:Namandje N Bumpus
-
依托单位:
Cellular Signaling in Drug-induced Toxicity
-
批准号:9336039
-
项目类别:
-
资助金额:$10.59万
-
财政年份:2013
-
负责人:Namandje N Bumpus
-
依托单位:
Tissue pharmacology imaging and modeling
-
批准号:9313780
-
项目类别:
-
资助金额:$59.63万
-
财政年份:--
-
负责人:Namandje N Bumpus
-
依托单位:
Tissue pharmacology imaging and modeling
-
批准号:8889597
-
项目类别:
-
资助金额:$52.38万
-
财政年份:--
-
负责人:Namandje N Bumpus
-
依托单位:
海外基金